Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Non-NRP2 mRNAs with seed-region complementarity refers to a population of messenger RNA (mRNA) transcripts that are unintentionally targeted by RNA interference (RNAi) molecules, such as siRNAs or miRNAs, designed to inhibit Neuropilin-2 (NRP2) [1]. This interaction is driven by the seed region of the small RNA—typically nucleotides 2 through 8—which can bind to complementary sequences in the 3' untranslated regions (UTRs) of various non-target mRNAs [2]. When this binding occurs, the RNA-induced silencing complex (RISC) may degrade these unintended transcripts or repress their translation, leading to off-target effects that can confound experimental results or cause clinical toxicity [3]. While NRP2 is a legitimate therapeutic target due to its role in promoting tumor angiogenesis, lymphangiogenesis, and metastasis, these complementary non-target mRNAs represent a significant hurdle in the development of highly specific RNAi-based drugs [1]. Monitoring these off-target interactions is essential during the preclinical development of NRP2-targeting agents to ensure that the observed phenotypic changes are due to NRP2 knockdown rather than the silencing of other essential genes [2]. Consequently, this term describes a safety-related phenomenon in pharmacology rather than a specific biological receptor or enzyme [3].
RNA interference (RNAi) mediated by the RISC complex, where the seed region of a guide RNA binds to complementary sequences in the 3' UTR of non-target mRNAs, leading to their degradation or translational inhibition [1][3].
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Non-Neuropilin-2 messenger RNAs with seed-region complementarity.